the novavax vaccine is like the flu vaccines that we have had in the past.tein based vaccine. doesn't have dna, and so it is not going to enter your cells. i think that was one of the things that people had a lot of concerns about. with the new vaccine coming out i think if we provide the proper education then we will see more people get the vaccine. >> let's hope so. dr. sheila young, thank you for joining me and thank you for all of the work you do in the community. i appreciate it. >> you as well. take care. >>> hundreds have lost their homes in the democratic republic of congo. but the danger is far from over. we'll have details live from there, next. stay with us. did you know prilosec otc can stop frequent heartburn before it begins? prilosec otc uses a unique delayed-release formula that works to turn down acid production, blocking heartburn at the source. with just one pill a day, you get 24-hour heartburn protection. take the prilosec otc two-week challenge. and see the difference for yourself. prilosec otc, 1 pill a day, 24 hours, zero heartburn. t

committing to receiving vaccines, the problem of course as soon as they heard johnson & johnson has a vaccine, novavax has a vaccine, moderna, whoever everybody started placing orders in the orders at the front of the line but the most money up front, canada put in enough orders to vaccinate every single canadian four times over, the united states put in enough to vaccinateri every american two times over. the uk is up around three times over in theory and someone in this means that chad has none, molly had 0 in vietnam struggles so where we are now is first of all as long as donald trump was president of the united states the u.s. was not part of it absolutely refused to participate in any way shape or form, one of the first things biden did in his first week was to commit $4 billion of u.s. money to.ov kovacs effort and i assume that money will process in the next threeil or four mons that will certainly help but kovacs, the last i looked it was 38 million short of its necessary funding that funding is essential to outbidding the rich countries to get actual vaccines in the facility for distribution

novavax vaccine is still in the development phase not yet approved for any age but it does expect toht, jonathan serrie , thank you very very much again we'll be monitoring governor ron desantis of florida. he will no doubt be outlining some of these measures he's taking to open up the state like immediately. we should let you know that disney, particularly disney world, will still be requiring masks in the interim out of abundance of caution and de suggestions that it sees fit. we're told that the governor is allowing businesses and local municipalities to do what they think is best, but that the edict from the state is any of this is necessary, anymore , sarah westwood on the implications, sarah with the washington examiner, cracker jack writer and follower of political events and sarah, if you knew you were coming here you'd think about the two early beneficiaries in the republican sweepstakes for 2024 leaving donald trump aside, governor ron desantis comes to mind with what he's doing in florida to deal with covid. even kristi noem in south dakota how she's responded without ever

vaccine, will there be a fourth? >> in the united states? >> in the u.s. >> could be because novavax and others are pursuing its vaccine. we right now in the united states we're hitting a point where it appears that we're going to have sufficient supplies for two reasons, one good, a lot people have gotten vaccinated. the other not so good because there are some people who apparently won't get vaccinated. so if you do that math and try to subtract, well, we have what we need or will need. on the other hand as i mentioned before there are variants of virus. right now we're hitting the warmest part of the year. come october, it's going to get cooler in many parts of the country when we typically see respiratory disease emerge. we think of it as the. you -- as the flu season until now. and for cold weather and variants, it could change the picture a little bit and there for might see more cases pick up, more transmission if people aren't vaccinated. so, i'm cautious in saying that it never hurts to have another authorization granted because that means we have just one more tool in our t

not quite as volatile as the other stocks that depend more on the covid vaccines as a barometer of the business like moderna, novavaxr vaccine we expect results on soon also the industry coming out not just against this philosophically but saying it wouldn't do very much. here's moderna ceo on their earnings call this morning. >> the manufacturinging company in the world, new technology you cannot go hire people who know how to make mrna. they don't exist we saw the news last night and made -- the news stream tonight. >> reporter: so bancel saying he is not losing sleep over this but experts say what would make is difference is a oirpgs warp speed international style to build up manufacturing capacity and not heard talk about doing something like that. >> where are most of today's vaccines made? are they made in the u.s.? are they made overseas, india? where? >> reporter: well, both moderna and pfizer have supply chains in the united states and in europe. johnson & johnson also has many partners around the world. and there's so many complications about countries not wanting to allow exports of vaccine and the united

decision but we are all very excited about the progress of the teesside vaccine as he calls it, the novavax vaccine the house with an update that there have now been over 450 million doses of the oxford astrazeneca vaccine deployed around the world at cost. that is the single biggest gift to the world that we could make with respect to vaccines. it is because of the attitude that this government took working with one of our greatest universities, working with one of a greatest industrial partners, it�*s another example of the big team effort that is helping, in this case, the whole world to get out of this pandemic. in a in this case, the whole world to get out of this pandemic.— out of this pandemic. in a pmqs in jul . out of this pandemic. in a pmqs in jul , i out of this pandemic. in a pmqs in july. i raised _ out of this pandemic. in a pmqs in july, i raised the i out of this pandemic. in a pmqs in july, i raised the concerns i out of this pandemic. in a pmqs in july, i raised the concerns of- out of this pandemic. in a pmqs in july, i raised the concerns of the i july, i raised the concerns of

week announced last week, all the work we are doing with moderna or oxford astrazeneca with the novavax vaccine research to look at which additional shot, piece of research to look at which additionalshot, is piece of research to look at which additional shot, is it novavax, astrazeneca, pfizer, orvalneva, which would deliver the greatest protection. we have to make that available to them and the nss team is already planning to be ready for deployment from september onwards —— the nhs team. the decision has not been made whether it will be september or early next year, that depends on the clinicians and how they feel the protection has lasted for the most vulnerable groups, and of course vaccine or virus variants that would be of concern we want to protect against like for example the south african variant.— south african variant. there is a bus a south african variant. there is a busy a trial _ south african variant. there is a busy a trial process _ south african variant. there is a busy a trial process to _ south african variant. there is a busy a trial process to go - south african variant.

. >> data really soon coming from novavax on its vaccine they are hoping for authorizations really around the world potentially in the third quarter. now, i asked him, there is some thought that the fda because we have three vaccines under emergency use authorization already may start asking companies that are still filing to pivot to full approval, which he said he's not expecting they are still expecting to go to the emergency use authorization route. but if they did have to file a bla, a full approval application, he said that wouldn't affect the timing of their filing but when the fda acts on it in terms of supply, that's very important as well. they have already manufactured 30 to 40 million doses they have faced delays in manufacturing and shortages of raw materials. he said by the end of this year they hope to be up to a rate of 200 million doses per month. next year 1.5 billion to 2 billion doses in the full year if they get everything onboard and all goes well, guys. looking forward to the future as well, we also talked about their plans in flu here's what stan erck said about th

. >>> on the vaccine front some movers novavax is delaying its timeline for ramping up vaccine production and does not expect to seek regulatory authorization for its shot until the third quarter of 2021 so pushing it back u.s. regulators have approved pfizer's shot for kids 12 to 15. that age group could start getting shots as soon as thursday, but the question is will the parents be getting it recent pew survey showed that less than a third of them wanted to vaccinate their kids under 18. >> novavax down 15% today. time for a cnbc news update. rahel solomon has it for us. >>> sirens sounding in tel aviv as hamas fires more than 100 rockets closing the country's main international airport israeli medics say that a 50-year-old woman was killed hamas says that the attack is retaliation for what it claims was israel's targeting of presidential towers in gaza. the u.s. state department says it is deeply concerned by the escalating violence and is calling on both sides to exercise restraint. >>> a prosecutor in georgia says she is seeking the death penalty for a 22-year-old man indicted for m

vaccines. there is a company called novavax. instead of giving the gene, you give the protein itself. novavax has done those trials. the preliminary data is promising. they have not been submitted for approval. host: this is from lizzie. if this is safe as you are saying, why are many doctors not taking the vaccine and advising patients not to get it? guest: i certainly have not experienced that at all. 99% of the physicians asked to get the vaccine get it. i do not know anyone who does not recommend it. this vaccine is the only way out of the pandemic. the data is clear that this vaccine is safe and effective. that might be a trope put out there by the act -- anti-vaccine movement. host: annette is joining us from philadelphia. caller: i hope this is not a repeat question. i just turned on the tv. if you are diagnosed with covid today, how are you treated at home? if you are hospitalized, are you only treated once your sites drop and you require oxygen? guest: if you have symptoms associated with covid and you are home, and you do not require hospitalization, there is not a specific

another two vaccines, the novavax and valneva jabs are currently pending approval. eed two doses to offer complete protection, so we are very keen to make sure that all those in a particularly high risk group, that is the over 50s and those with underlying illness, receive their second vaccination as soon as feasible. and we are reaching out to those individuals that have not been vaccinated so far. so it is an evolving situation, it is of concern. we do need to carry on vaccinating at pace, and if we do do that, then we will provide some significant protection against this variant. into some significant protection against this variant. ., ., ., some significant protection against this variant-— this variant. into a new look at the numbers of— this variant. into a new look at the numbers of cases _ this variant. into a new look at the numbers of cases going _ this variant. into a new look at the numbers of cases going up, - this variant. into a new look at the numbers of cases going up, and i this variant. into a new look at the l numbers of cases going up, and yet t

alix: novavax shares down over the past is two trading days after the company had to push back the timeline for its covid vaccinehe bottom with the ceo of novavax, stan erck. the question everyone wants to know is why you keep having delays? stan: it a good question. we are in good shape. our starting point was a year ago. we have all of the manufacturing data put together into a package. this has been to all of the global regulatory agencies. with that we submit all of the clinical efficacy and safety data. we have some of the best clinical and safety data that exists. we have that put together. we are assembling the manufacturing package and frankly a year ago we had zero manufacturing capacity, zero analytical and process develop laboratories. we have built that all in a year , eight different countries. that is what has taken us longer. we are there. all of the data -- i think we are in good shape. guy: there is no problem with the vaccine? this is a manufacturing issue, not a vaccine issue. stan: we have sown consistently we have a great vaccine. we are about to unwind u.s. trial that is 30,000 people in a

vaccine space. if you look at novavax, which is expecting phase three data here in the u.s. ts covid vaccine. curevac which is another mrna player, which is expecting data soon biontech, of course, which is pfizer's partner, all of these stocks down about 7% to 9% on this patent news >> seth: wow, joe biden, scourge of big pharma! who would have thunk it? although, to me, it makes sense, because biden does have the energy of a grandpa who refuses to take over-the-counter meds and insists a "swim in the lake" will cure his back pain. "in my day, if you had a back ache, you ate some ground liverwort and rubbed some vinegar on it. and if it got really bad, you went down to dr. bonker's medical wagon and drank some of his magic elixir it didn't have no tylenol or ibuprofen in it, just straight whiskey and cocaine. but it's truly difficult to underscore just how monumental and historic this is with one decision, joe biden sent big pharma stock prices plummeting, and put people's lives over profits and he didn't make a big flashy rose garden announcement, or film a weird video wher

vaccine production on scene. you will have 3 billion doses of moderna, novavax, and astrazeneca and johnson & johnson and pfizer. and of course the russian and the chinese vaccines. you will have a lot of vaccines next year. i think longer term it's worth looking at some of these questions and obligations. maybe this is just my experience in government, i'm just for the moment looking at hard minded practical solutions. amb. green: i think that the report that the tony blair institute has put forward i think strikes the right balance. i think it is enormously practical in the sense that there are concrete steps for policymakers for both national and international policymakers that present the roadmap to success. in the longer run there are a number of things we should take on and be thinking about. every nation already has reporting requirements. i do think in the long run we should be beefing things up. i think we have to in the long run avoid the risk of fighting the last war, that's always a challenge to us and i was -- i had a professor show me a series of slides, photographs of lab to the u.s. government had

and so i think all of these put together determine how your vaccine stacks up. emily: the novavaxcoming up, you did not think we would forget about it, did you? the epic epic games high-stakes antitrust trial still underway. we will bring you this week's action and a look ahead to when the ceo tim cook will take the stand. this is bloomberg. ♪ >> the apple versus epic antitrust trial is on week two of arguments inside of apple's app store is a monopoly. today, a hint of a potential compromise floated by the judge. let's bring in mark gurman who has been of course covering this trial from day one. what is the latest? mark: we are in one of the more boring periods of the trial. this is where the economists are going head-to-head to make their case. if apple's profit margins are monopoly-like, what changes should they have to make to the app store? one of the more interesting things that happened this week was the judge actually floated a compromise for apple and epic, actually something i think we talked about about a month ago. i certainly wrote about it on the website. basically t

when you combine that with the likely chance of new vaccines — like novavax — being approved by in theon _ extra doses the summer? i think the administration clearly _ extra doses the summer? i think the administration clearly has _ extra doses the summer? i think the administration clearly has to - extra doses the summer? i think the administration clearly has to take i extra doses the summer? i think the administration clearly has to take a l administration clearly has to take a strong leadership role and giving the world vaccinated, notjust what we do the surplus but leadership as well as providing vaccines. as the joe biden administration started, they were laser focused on the needs of us citizens and getting the american population vaccinated. but mindful of the global context. this is a global pandemic in the country will be completely safe until all countries are safe. in addition, there is a humanitarian need, which is glaringly evident now as we look at what is happening in india as well as the tragedy in brazil and elsewhere. so, this is a critical moment after continued to

vaccine production on scene. you will have 3 billion doses of moderna, novavax, and astrazeneca and johnson & johnson and pfizer. and of course the russian and the chinese vaccines. you will have a lot of vaccines next year. i think longer term it's worth looking at some of these questions and obligations. maybe this is just my experience in government, i'm just for the moment looking at hard minded practical solutions. amb. green: i think that the report that the tony blair institute has put forward i think strikes the right balance. i think it is enormously practical in the sense that there are concrete steps for policymakers for both national and international policymakers that present the roadmap to success. in the longer run there are a number of things we should take on and be thinking about. every nation already has reporting requirements. i do think in the long run we should be beefing things up. i think we have to in the long run avoid the risk of fighting the last war, that's always a challenge to us and i was -- i had a professor show me a series of slides, photographs of lab to the u.s. government had

vaccines. there is a company called novavax. instead of giving the gene, you give the protein itself. novavax has done those trials. the preliminary data is promising. they have not been submitted for approval. host: this is from lizzie. if this is safe as you are saying, why are many doctors not taking the vaccine and advising patients not to get it? guest: i certainly have not experienced that at all. 99% of the physicians asked to get the vaccine get it. i do not know anyone who does not recommend it. this vaccine is the only way out of the pandemic. the data is clear that this vaccine is safe and effective. that might be a trope put out there by the act -- anti-vaccine movement. host: annette is joining us from philadelphia. caller: i hope this is not a repeat question. i just turned on the tv. if you are diagnosed with covid today, how are you treated at home? if you are hospitalized, are you only treated once your sites drop and you require oxygen? guest: if you have symptoms associated with covid and you are home, and you do not require hospitalization, there is not a specific

as of may 6, last thursday where the 450 million doses of the two shot vaccine have been supplied to 91 different countries, novavax sinking into the red at this hour despite the fact that we have reports that the covid flu vaccine is showing profits in early trials shares are faltering nine and half% after the washington post reported bill gates backed biotech might not seek emergency use authorization for covid inoculates until june. that is next month, big deal. give it time people. electric truck makers losing its charge after flashing the 2021 production target by 800 units to 1000 blaming global supply chain issues, workforce pulling back by 13% let's check ed makers getting into the close we have tesla, talking about elon musk and the crypto story down 5.5%, lordstown seven and a quarter and fisk are down 9%. "the claman countdown" is always looking to help you guys stay honest when it comes to investing take a look at shares of honest they founded by actress jessica alba, shares are down for a third straight trading day losing 11.8% since topping 44% during the market debut last wednesday. star power not al

vaccines are not being exported from reasons we can understand. the u.s. contribution enabled kovacs to get back on the market so i'm start happy to report they've recently concluded deals with moderna and novavax so there are more vaccines moving into the system but there's not enough as you rightly pointed out and if i may briefly explain the framework which we are using for the foundation of our global response. the first is on obviously vaccine, increasing supply and access globally because we all know the safety of the american people and everywhere depends on our ability to defeat virus with no borders. the second is to reduce mortalities that also is transmission. we know from our own experience even before we were able before the vaccine, preventing transmission is key as is the underlying health systems upon which we in all countries depend. the third is to deal with acute shots, economic and otherwise that are the result of this pandemic, the economic and other systematic impact. we seen entire sectors collapse in many countries around the world. finally, work on building global health security that we know we need for the future because we know we will see more threats like this. let

my question is this, during the past 5 two weeks, novavax a 33-year-old company yet to produce a vaccine hit a high of $331 per share albeit receiving 1.6 from the federal government. a 13-year-old company who only vaccinated the covid vaccine hit $213 per share moderna a 10-year-old company only produced the covid vaccine thus far only reached a high of $189 per share moderna received federal planning of $1 billion and a federal contact -- >> i can tell you the answer novavax isn't worth what it's selling for and moderna isn't, either novavax should be lower and moderna should be much higher because moderna has so many other things in the fire i love that company. i think it's terrific, but you know what? nate speaks to them in the morning. i had it first when the stock was at $18 i said smart guy >>> the jobs numbers turned out to be good news for the stock market and with the fed on their side, we can keep climbing on "mad" tonight as people become vaccinated, is planet fitness looking to be in good shape and jessica al ba's longest running role, the company she co-founded but is it w

vaccine. will there be a fourth? guest: in the united states? host: in the u.s.. guest: there could be. novavaxng its vaccine. right now in the united states, we are heading a point where the fear is we will have sufficient supplies for two reasons. many have gotten vaccinated. but some will not get vaccinated. if you do that math and try to project, " well, we have what we need." there are variants of the virus. we will hit the -- we are hitting the warmest part of the year. in october is when we see respiratory viruses emerge. between the emergence of cold weather and variants, it could change the picture a little bit and we therefore might see more cases take up, mort transition -- tick up, more transmission. it is never bad to have another authorization granted. host: we will conclude on that note, reminding our listeners and viewers that ed silverman right -- writes for staten news. -- this is -- host: this is the headline from the associated press. here are the details courtesy of the ap. the house expected to vote this week on two bills aimed at preventing more attacks on the u.s. capito

vaccine space. if you look at novavax, which is expecting phase 3 data in the u.s. soon for its covid vaccine.ecting data soon. biontech, all stocks down 7 to 9% on the patent news. guys. >> in the meantime, more broadly, the pace of daily vaccinations in this country, the 7-day average is down about a third from the peak. if we get clearance on 12 to 17-year-olds, or 12 to 15-year-olds, i guess, i imagine that's going to be net positive for vaccination rates in the u.s. >> pfizer's ceo was asked that, he did hope and expect once they got clearance for that population of folks, there would be a lot more people going to get vaccinated interestingly, there was a poll out from kaiser family foundation, saying among adults, people who have not been vaccinated, there are 9% who say they still plan to get vaccinated in terms of the adult population, we are mirroring the end of people who it's going to be easy to get to. >> meg, real quickly, how concerned do you think people are in the industry about the waiver on ip, and whether or not it is a one time deal or whether it should be viewed as perhaps

if you take novavax as a guide, shelley has ordered 51 million doses of that vaccine, but approval delaysat might not be delivered by september as hoped. so these things do take time. but once it is approved, moderna will be a third vaccine alongside pfizer -- or zeneca. astrazeneca of course is locally produced. moderna is mostly produced in the u.s. moderna is in talks with the government to look at potential local manufacturing opportunities here, but that also would take time potentially up to two years, because there is no local manufacturing capability in australia for mnra vaccines. shery: you mentioned the speed of the vaccine rollout in australia has been criticized for being too slow. are things improving? paul: very gradually. it is not getting worse, i will put it that way. almost 2.7 million doses administered to a population of just over 24 million. in the past week there has been 400,000 astrazeneca shots given to those over 50. a new batch of 350,000 pfizer vaccines arrived monday, that is being administered to 40 to 49-year-old. more are getting rolled out every day. the

a 4th vaccine might meanwhile could be available in the u.s. this year. the company novavax says it will try to get an emergency authorization for its drug later this year. officials with the biotech firm had hoped to get their vaccine reviewed by the end of june. but so far that's been delayed. the maryland based company says it's also hoping to get its 2 shot vaccine authorized in europe here. very latest vaccine numbers here in california tonight. 45% of the golden state's eligible population now fully vaccinated an additional 16 and a half percent have received at least one dose of the pfizer or moderna vaccines. >> next on kron 4 news at 10 police say it is happening and what they describe as epidemic proportions. what you need to know about a rise in catalytic converter thefts also, have you seen this man. this is a suspect sketch. what he is accused of doing to a 13 year-old girl and a good sign for governor newsome. what a new poll is saying about his chances in the special >> terrible. you specially these days. you know, but people did they don't have job. this prob

novavax righ. down 11.5% there are big hurdles in getting out the covid vaccine.e after this. >> announcer: today's big number 60.9%. that's the jump in the average price of a gallon of gas compared to last year. according to aaa analysts expect the price at the li hheontinue to cmbigr with the largest pipeline in the u.s. shutdown. state-of-the-art but dependable. in other words, you want a hybrid. so do telcos. that's why they're going hybrid with ibm. a hybrid cloud approach with watson ai helps them roll out new innovations anywhere without losing speed. from telco to transportation, businesses are going with a smarter hybrid cloud, using the tools, platform and expertise of ibm. good work little buddy. ♪ ♪ ♪ ♪ when i was young ♪ no-no-no-no-no please please no. ♪ i never needed anyone. ♪ front desk. yes, hello... i'm so... please hold. ♪ those days are done. ♪ i got you. ♪ all by yourself. ♪ go with us and find millions of flexible options. all in our app. expedia. it matters who you travel with. (♪ ♪) whether it's a technology first, (♪ ♪) a fashion first, (

fox two news, the prospect of drug companies losing patents on vaccines that some pharma stocks tumbling today. shares of moderna, novavax, bio and tech and fizer all dropped sharply on the news. however, shares of fizer and johnson and johnson mostly recovered by the end of the trading day, new 10 san francisco is reopening, but the city's mosconi center got some disappointing news. a major convention decided to go virtual and cancel. it's in person meeting this fall. ktvu jana katsuyama is here now with the reality for businesses trying to rebound in travel and tourism industry, janna. well, san francisco travel experts say one of the big problems is that so many of the tourist and convention and 10 g's are international, so the city with the pandemic currently raging will need to make some adjustments in order to adapt. their sounds of life slowly getting back to normal at the palace restaurant in san francisco. it's just a block away from the mosconi convention center. but this week bad news, the american college of rheumatology told the mosconi center, it decided to cancel its in person, november 2021 convention and

randomly selected to have one of seven different covid vaccines, and we have all heard of the astrazeneca, pfizer and moderna jabs, but then there is novavaxich are currently awaiting approval, and two lesser known ones, curevac and valneva, currently going through trials. the uk government has bought huge supplies of all. the trial will look at safety because we know mixing different vaccines can increase short—term side effects, an increased chance of fever, fatigue, sore arms, and it will look at antibody levels, how much we boost does it give, and some volunteers will get a half dose, which might be enough to give protection. the results will help decide if we need a booster campaign this autumn, because it has not been decided yet. it mightjust be some age groups that require it. if you are fully immunised, over30 that require it. if you are fully immunised, over 30 and want to sign up, you can go to the cov—boost website at the university of southampton. let's take a look at the latest official figures for the pandemic in the uk. there were 2,696 new coronavirus infections recorded in the latest 24—hour period, which means that, on a

novavax. jpmorgan is questioning their ability to make vaccine at scale. they're losing confidence. mrna, when they first started coming out and pfizer and moderna, you had all these restrictions about how you had to send it it had to be ice cold. that's over. they're saying the manufacturer's challenges aren't going away and they no longer have a product that is going to take the -- if they ever get it out, take the country by storm it's very damning piece by jpmorgan i didn't like it they really -- i'm not sure it was -- i know when i read it asaid wow, this stock is going to get hammered. not yet. >> yep definitely discouraging, especially after we got some indication earlier in the week they might have a combo shot for covid and flu, but we'll watch that we never got to wendy's and their raised guidance. you have them tonight. >> yeah. this is not -- this is not just because of my wife's voracious eating of the baconator. she had the double i put it on twitter. she wasn't happy about that. wynn, we have to talk about this interactive deal with bill foley. another spac guy and th

in a move it said will allow it to provide covid-19 vaccines in the third quarter. nov novavaxon and they got a tough tax bill. the founder died, i guess, last year >> yeah. >> their tax bill is $11 billion. $11 billion tax bill so, they've got 23,000 monets, picassos and dalis. >> wow >> not just those three, but that is an example that is quite a elecollection amassed over a lifetime of the founder. >> they've got to unload that to pay the tax bill >> part of it -- yeah, i'm not sure exactly how state taxes work in south korea, obviously but that's something -- just that sheer number. >> christi's, like what are they thinking at the auction houses right now. >> an avid collector, obviously. it would be neat to do that, i got to admit, to be able to buy whatever -- any monet that you'd like i've -- i've always asked the guy for a suitene, i loved over in paris, i saw it and they just -- there's none for 800 bucks. there's just no way >> you're out of luck. >> i asked they laughed at me it's not going to happen i don't own any. >> you're not going to be able to buy a seat, you'

expanding the manufacturing, but novavax has been spending money developing technology for over 30 years. let's turn this on its head. let's stop all pharma companies doing vaccine and just the government spent money on developing vaccines. where do you think we would be? lisa: this is the argument. there is a more efficient allocation of resources within the private sector than the public sector. that is the heart of the debate of a lot of people have been having for decades and decades. going forward, how much does this effect the development of new drugs if this ip waiver does go through? sam: if it becomes a reality, and if it becomes -- if it actually has bite. we have to watch with politicians how much there is substance versus form. if it becomes a reality, i would suggest anyone who wants to invest in developing future drugs will have to think twice about putting money in their pockets. tom: we are all dancing on a pin. let me cut to the chase. viagra made a ton of money at pfizer. i had nothing to do with that profit. viagra is a blue pill. this is about people dying. what it we move onto a new modern landscape of pharmaceutical intellectual property wh

a lead, but johnson & johnson, moderna, and then vaccine manufacturers, nicole, that are really dominant in the rest of the world, astrazeneca and novavaxs are doing trials in children, and i think the tension that's now starting to kind of flare up is that we will have viable vaccines most likely for children as young as 6 months to 2 years all the way up through 18. there's a debate sparking about whether or not we should defer those vaccines to allow for other countries that don't have this access because we might see rates that are so low in our country that it makes the kind of ethical question come forward of, should we vaccinate our children? i think we should. i think we need to, to get our schools in order, but it is an important question we'll have to answer. >> yeah, i mean, i was going to ask you about mental health arguments have been made by members of both political parties after a year and four months of remote school and i wonder how you think those will figure into that debate you predict. >> yeah, i do think that certainly for the safety of everybody involved, including faculty, staff, students, all alike, there is go

vaccines. there is a company called novavax. instead of giving the gene, you give the protein itself.ovavax has done those trials. the preliminary data is promising. they have not been submitted for approval. host: this is from lizzie. if this is safe as you are saying, why are many doctors not taking the vaccine and advising patients not to get it? guest: i certainly have not experienced that at all. 99% of the physicians asked to get the vaccine get it. i do not know anyone who does not recommend it. this vaccine is the only way out of the pandemic. the data is clear that this vaccine is safe and effective. that might be a trope put out there by the act -- anti-vaccine movement. host: annette is joining us from philadelphia. caller: i hope this is not a repeat question. i just turned on the tv. if you are diagnosed with covid today, how are you treated at home? if you are hospitalized, are you only treated once your sites drop and you require oxygen? guest: if you have symptoms associated with covid and you are home, and you do not require hospitalization, there is not a specific tr

been working on the vaccines, particularly the mrna vaccine so successful like pfizer, moderna, moderna has been working on it for a decade. novavaxeen at it for three decades and we'll just hand over all of that technology to whom? to the chinese. the chinese as you mentioned has a vaccine that doesn't work very well. the seychelles islands is the most recent area they are using the chinese vaccine, they're having all postvaccine problems with covid. also the same in brazil. chinese vaccines. same in india. chinese vaccines. chinese vaccine doesn't work. we'll hand them all of this, but it will take them a long time to develop, even if there wasn't a factor of stealing all this intellectual property. it is going to take them a long time to gear up with this new technology. we, meanwhile, could be producing with american workers all the vaccines necessary for the whole world? >> right. also people talk about, you know, where is the equity, where is the equality or inequality as a result of these out comes, china is not paying us for the fact of the impact of lives on our economy, effect of virus. success of capitalism of our syste

generally what's been the mood around some of your clients around these vaccine stocks so much excitement at first for a company like novavax data looked good and now it's taking a little bit of time and we might not need as much in the u.s. which is obviously a good problem, but what's the vibe on these stocks? >> i think going into all of the pharmaceuticals during the pandemic was an interesting play for people first of all, everybody knew how challenging it was with the numbers around how long it had taken for vaccines in the past it was also unclear how much profit, and obviously we got incremental news on this with the conversation around u.s. patent protection or lack thereof, around whether the revenues and the research would accrue to these companies in realtime irrespective of what happens long term with patent protection here, what you're going to find is that it will. all of the research, all of the international and monetary capital that went into the creation of vaccines is going to accrue to other for sale more profitable products. so last week there was definitely a sense of disappointment and especially wit

pandemic supports the waiver of those protections for covid-19 vaccines so you are now seeing quite a reaction from stocks like moderna. novavax here in the u.s united stateser to a lesser extent and its partner biontech, seeing those drop precipitously it is a complex issue, but the industry has been warning that this will not solve the problem. in the longer term sense, it could deter companies from working on solutions like this during the next pandemic you know, brent sonders, the ceo of aller began taking to twitter to say who will make the vaccine the next time? that's similar to what we heard from the pfizer ceo yesterday who argued that the bottleneck is the raw materials and that it will take time for other industries to make these vaccines obviously not a fan this news. but public health folks cheering the news today. >> is this not different, though n the fact that you do have some of the companies who did make the vaccine this time around and haven't made a profit from it? so there is the good will that existed in a massive crisis like this for some big pharma companies to still take the action to make the vaccine.